Zevra Therapeutics, Inc. (ZVRA) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Royalties and Other Reimbursements under the AZSTARYS License Agreement | 1.1M | FY2026-Q1 |
| Net Revenue from MyPlypha | 24.6M | FY2026-Q1 |
| Net Revenue from Olpruva | 300K | FY2026-Q1 |
| Net Reimbursements from the French Expanded Access Program for Arimoclomol | 2.4M | FY2025-Q3 |
Back to ZVRA overview · ZVRA earnings · ZVRA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.